Discovery of genetic interactions in cancer

发现癌症中的遗传相互作用

• 批准号: 10702681
• 负责人: Eytan Ruppin
• 金额: $ 272.07万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10702681
• 关键词: Advanced Malignant Neoplasm; Antineoplastic Agents; Cancer Patient; Clinical; Complement; Data; Development; Drug Targeting; Drug resistance pathway; Drug usage; Effectiveness; Genes; Genetic; Genomics; Laboratories; Malignant Neoplasms; Mediating; Methods; Mutation; Patients; Pharmaceutical Preparations; Pharmacotherapy; Research; Resistance; Sampling; Therapeutic; Work; actionable mutation; anticancer research; base; cancer genetics; cancer therapy; cohort; dosage; drug development; fighting; genome-wide; improved; patient stratification; precision medicine; predicting response; response; targeted treatment; tool; transcriptomics; tumor; whole genome

This approach provides a basis for new combination-based therapeutic strategies improving the effectiveness of existing cancer therapies by identifying and targeting drug resistance pathways. Going forward in this line of research, having just established our laboratory recently, we intend to explore two main paths: (a) precision medicine - inferring patient specific GI-mediated drug response by analyzing the transcriptomics of their tumors, and (b) drug development - identifying new SL-based drug targets, combined with their SL-derived patient stratification profiles.

这种方法为新的基于组合的治疗策略提供了基础，通过识别和靶向耐药途径来提高现有癌症疗法的有效性。在这一研究方向上，我们最近刚刚建立了实验室，打算探索两条主要路径：（a）精准医学 - 通过分析肿瘤的转录组学来推断患者特异性胃肠道介导的药物反应，以及（b）药物开发 - 确定新的基于 SL 的药物靶点，结合其 SL 衍生的患者分层概况。